1st Quarter - Report
OGR for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)
Firm
Income
$50,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
General prescription drug affordability and access. Intellectual Property issues. PDUFA Reauthorization. Provisions related to the pharmaceutical industry; FY2022 Consolidated Appropriations Act (H.R.2471, P.L.117-103); H.R.7007, COVID Supplemental Appropriations Act, 2022.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN AGUILLEN | — |
| JEROME MURRAY | — |
| KARISSA WILLHITE | — |
Medicare/Medicaid MMM
Medicare Part D access and drug pricing negotiation; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376). Compulsory licensing policy issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN AGUILLEN | — |
| JEROME MURRAY | — |
| KARISSA WILLHITE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.